



Bal Pharma Limited

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

21.02.2023

BSE Limited
Mumbai.

Dear Sir ,

Sub : Intimation on dispute resolution mechanism.
Ref : Regulation 30 of the SEBI (LODR) Regulations, 2015

With reference to the above cited subject and reference , we would like to inform the exchanges that our Company through its STA has completed the activity of sending email / SMS's to all the physical shareholders whose email / contact number's are registered with the Company , in compliance with the SEBI Circular # SEBI/HO/OIAE/2023/03394 dated January 27, 2023 regarding availability of Dispute resolution mechanism at Stock Exchanges against listed companies / Registrar to an Issue and Share Transfer Agents.

Our Share transfer agents M/s.TSR consultants Pvt Ltd has confirmed the completion of the activity of communicating with our shareholders on 10.02.2022 and also has submitted the action taken report in specified format to SEBI, on 18.02.2023.

Please take this intimation on record.

For Bal Pharma Ltd

V

HIMESH

Authorised Signatory

Digitally signed by HIMESH
DN: cn=B, postalCode=560011, st=KARNATAKA,
serialNumber=1, email=HIMESH@BALPHARMA.COM, o=Bal Pharma,
emailNumber=08859751392879709513a99f
05d98776ac24267070776c97133206,
serialNumber=39,2671730210946202724581a,
c=IN, email=HIMESH@BALPHARMA.COM, o=Bal Pharma,
2023.02.21 12:53:03+05'30'
Date: 2023.02.21 12:53:03+05'30'

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820